MedTrace Logo

Rituximab Therapy for Steroid-Refractory Chronic Graft Versus Host Disease

NCT00136396 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2013-06-12

No results posted yet for this study

Summary

The purpose of this study is to determine if rituximab is a safe and effective therapy for steroid-refractory chronic graft versus host disease (GVHD).

Conditions

  • Graft vs Host Disease

Interventions

DRUG

Rituximab

Given once weekly for 4 weeks followed by a 4 week observation therapy.

Sponsors & Collaborators

Principal Investigators

  • Corey S. Cutler, MD, MPH · Dana-Farber Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-01-31
Primary Completion
2006-11-30
Completion
2010-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00136396 on ClinicalTrials.gov